These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9406679)

  • 1. Carnitine and its derivatives in cardiovascular disease.
    Arsenian MA
    Prog Cardiovasc Dis; 1997; 40(3):265-86. PubMed ID: 9406679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carnitine and its role in cardiovascular disease.
    Retter AS
    Heart Dis; 1999; 1(2):108-13. PubMed ID: 11720611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review.
    Ferrari R; Merli E; Cicchitelli G; Mele D; Fucili A; Ceconi C
    Ann N Y Acad Sci; 2004 Nov; 1033():79-91. PubMed ID: 15591005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New thoughts of pathophysiology and therapy of ischemic heart disease.
    Pepine CJ
    Cardiologia; 1991 Dec; 36(12 Suppl 1):373-7. PubMed ID: 1841793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass.
    Lango R; Smolenski RT; Narkiewicz M; Suchorzewska J; Lysiak-Szydlowska W
    Cardiovasc Res; 2001 Jul; 51(1):21-9. PubMed ID: 11399244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts.
    Cui J; Das DK; Bertelli A; Tosaki A
    Mol Cell Biochem; 2003 Dec; 254(1-2):227-34. PubMed ID: 14674702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic potential of carnitine in cardiovascular disorders.
    Pepine CJ
    Clin Ther; 1991; 13(1):2-21; discussion 1. PubMed ID: 2029724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS; Hill JA
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders.
    Mingorance C; Rodríguez-Rodríguez R; Justo ML; Alvarez de Sotomayor M; Herrera MD
    Vasc Health Risk Manag; 2011; 7():169-76. PubMed ID: 21490942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive and negative outcomes of L-arginine therapy in cardiovascular diseases.
    Herbaczyńska-Cedro K
    J Physiol Pharmacol; 1999 Dec; 50(4):653-60. PubMed ID: 10639015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carnitine derivatives: clinical usefulness.
    Malaguarnera M
    Curr Opin Gastroenterol; 2012 Mar; 28(2):166-76. PubMed ID: 22333562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beneficial effects of propionyl L-carnitine on sarcolemmal changes in congestive heart failure due to myocardial infarction.
    Sethi R; Dhalla KS; Ganguly PK; Ferrari R; Dhalla NS
    Cardiovasc Res; 1999 Jun; 42(3):607-15. PubMed ID: 10533600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propionyl l-carnitine: intermittent claudication and peripheral arterial disease.
    Andreozzi GM
    Expert Opin Pharmacother; 2009 Nov; 10(16):2697-707. PubMed ID: 19827991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of calcium channel blockers in the treatment of cardiovascular diseases.
    Herman ZS
    Pol J Pharmacol; 1999; 51(2):201-6. PubMed ID: 10425650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early effects of cardiovascular drugs--do they predict clinical outcomes?
    Carruthers SG
    Int J Clin Pharmacol Ther; 1994 Mar; 32(3):107-12. PubMed ID: 8205369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Consensus conference on the therapeutic effects of L-carnitine in patients with myocardial ischemia and left ventricular remodeling].
    Praxis (Bern 1994); 1998 Jan; 87(4):95-113. PubMed ID: 9522637
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological effects of meldonium: Biochemical mechanisms and biomarkers of cardiometabolic activity.
    Dambrova M; Makrecka-Kuka M; Vilskersts R; Makarova E; Kuka J; Liepinsh E
    Pharmacol Res; 2016 Nov; 113(Pt B):771-780. PubMed ID: 26850121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperfusion injury: the possible role of iron chelation.
    Reznick AZ; Kagan VE; Ramsey R; Tsuchiya M; Khwaja S; Serbinova EA; Packer L
    Arch Biochem Biophys; 1992 Aug; 296(2):394-401. PubMed ID: 1321584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of L-carnitine and its acetyl and propionyl esters on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 31P-NMR spectroscopy.
    Löster H; Keller T; Grommisch J; Gründer W
    Mol Cell Biochem; 1999 Oct; 200(1-2):93-102. PubMed ID: 10569188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. l-Carnitine and heart disease.
    Wang ZY; Liu YY; Liu GH; Lu HB; Mao CY
    Life Sci; 2018 Feb; 194():88-97. PubMed ID: 29241711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.